Leo Pharma to initiate early-stage trial in inflammatory diseases
A phase I trial will test a new candidate with potentially ”broad use within inflammatory diseases,” the dermatology firm says.
by christopher due karlsson & christian bundgaard, translated by daniel pedersen
Leo Pharma is expected to initiate a phase I trial of a new drug candidate named Leo 158969 in February, according to database Clinical Trials.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Extensive layoffs at Leo Pharma – 300 jobs lost
For subscribers
